106 reports of this reaction
5.3% of all ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL reports
#2 most reported adverse reaction
DISEASE RECURRENCE is the #2 most commonly reported adverse reaction for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, manufactured by The Procter & Gamble Manufacturing Company. There are 106 FDA adverse event reports linking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL to DISEASE RECURRENCE. This represents approximately 5.3% of all 1,997 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL who experience disease recurrence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE RECURRENCE is moderately reported among ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL users, representing a notable but not dominant share of adverse events.
In addition to disease recurrence, the following adverse reactions have been reported for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL:
The following drugs have also been linked to disease recurrence in FDA adverse event reports:
DISEASE RECURRENCE has been reported as an adverse event in 106 FDA reports for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE RECURRENCE accounts for approximately 5.3% of all adverse event reports for ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, making it one of the most commonly reported side effect.
If you experience disease recurrence while taking ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.